Evaluation of the Duration of Oral Combination Therapy in Type 2 Diabetes, Prior to the Initiation of Insulin in the UK

This study has been completed.
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00995995
First received: October 15, 2009
Last updated: June 16, 2011
Last verified: June 2011
  Purpose

Carry out the cost-effectiveness analysis of rosiglitazone on a population in line with the rosiglitazone license and using UK costs


Condition Intervention
Diabetes Mellitus, Type 2
Drug: Rosiglitazone

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Evaluation of the Duration of Oral Combination Therapy in Type 2 Diabetes, Prior to the Initiation of Insulin in the UK

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Cost-effectiveness of rosiglitazone [ Time Frame: From literature ] [ Designated as safety issue: No ]

Enrollment: 7641
Study Start Date: October 2008
Study Completion Date: February 2009
Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
All patients Drug: Rosiglitazone
Rosiglitazone

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Adults - obtainable from the literature

Criteria

Inclusion Criteria:

  • Rosiglitazone Type II Diabetes studies

Exclusion Criteria:

  • Studies without the required outcome
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00995995

Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: Cheri Hudson; Clinical Disclosure Advisor, GSK Clinical Disclosure
ClinicalTrials.gov Identifier: NCT00995995     History of Changes
Other Study ID Numbers: 113030
Study First Received: October 15, 2009
Last Updated: June 16, 2011
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Rosiglitazone
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on April 15, 2014